Hypomethylation-induced regulatory programs in T cells unveiled by transcriptomic analyses
暂无分享,去创建一个
E. Yannaki | C. Pierides | Panagiota Stamou | Dionysia Kefala | Memnon Lysandrou | N. Savvopoulos | Panayiota Christofi | Maria Kyriakou | Anastasia Papadopoulou | Paul Costeas | Alexandros Spyridonidis | M. Lysandrou
[1] G. Karavalakis,et al. Study protocol: Phase I/II trial of induced HLA-G+ regulatory T cells in patients undergoing allogeneic hematopoietic cell transplantation from an HLA-matched sibling donor , 2023, Frontiers in Medicine.
[2] A. Pradier,et al. Analysis of T cell Repertoire and Transcriptome Identifies Mechanisms of Regulatory T cell (Treg) Suppression of GvHD. , 2022, Blood.
[3] Mark M. Davis,et al. Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients , 2021, Science Translational Medicine.
[4] M. Roncarolo,et al. Pre-clinical development and molecular characterization of an engineered type 1 regulatory T-cell product suitable for immunotherapy. , 2021, Cytotherapy.
[5] M. Kobor,et al. Optimized CRISPR-mediated gene knockin reveals FOXP3-independent maintenance of human Treg identity. , 2021, Cell reports.
[6] Andrew J. Pollard,et al. RNA2HLA: HLA-based quality control of RNA-seq datasets , 2021, Briefings Bioinform..
[7] Y. Okada,et al. Regulatory T Cell-Specific Epigenomic Region Variants Are a Key Determinant of Susceptibility to Common Autoimmune Diseases. , 2020, Immunity.
[8] A. Thomson,et al. In situ recruitment of regulatory T cells promotes donor-specific tolerance in vascularized composite allotransplantation , 2020, Science Advances.
[9] J. Bluestone,et al. Treg cell-based therapies: challenges and perspectives , 2019, Nature Reviews Immunology.
[10] D. Miklos,et al. Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. , 2019, JCI insight.
[11] I. Pe’er,et al. arcasHLA: high-resolution HLA typing from RNAseq , 2018, bioRxiv.
[12] A. Sgourou,et al. Simple in vitro generation of human leukocyte antigen-G-expressing T-regulatory cells through pharmacological hypomethylation for adoptive cellular immunotherapy against graft-versus-host disease. , 2017, Cytotherapy.
[13] Lirong Pei,et al. Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers , 2017, Cancer Immunology Research.
[14] M. Obach,et al. CCL22 Prevents Rejection of Mouse Islet Allografts and Induces Donor-Specific Tolerance , 2015, Cell transplantation.
[15] H. Wiendl,et al. Human CD4+HLA‐G+ regulatory T cells are potent suppressors of graft‐versus‐host disease in vivo , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[16] P. Oefner,et al. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. , 2014, Blood.
[17] Y. Hildebrandt,et al. 5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity , 2014, Mediators of inflammation.
[18] J. Castle,et al. HLA typing from RNA-Seq sequence reads , 2012, Genome Medicine.
[19] K. Nakai,et al. T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. , 2012, Immunity.
[20] H. Papadaki,et al. Identification of a novel HLA-G+ regulatory population in blood: expansion after allogeneic transplantation and de novo HLA-G expression at graft-versus-host disease sites , 2012, Haematologica.
[21] M. Levings,et al. Prevention of murine autoimmune diabetes by CCL22-mediated Treg recruitment to the pancreatic islets. , 2011, The Journal of clinical investigation.
[22] J. Fechner,et al. An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells , 2010, The Journal of Immunology.
[23] W. Shannon,et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. , 2010, Blood.
[24] D. Munn,et al. Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. , 2009, Blood.
[25] J. Blay,et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. , 2009, Cancer research.
[26] N. Rouas-Freiss,et al. Beyond the increasing complexity of the immunomodulatory HLA-G molecule. , 2008, Blood.
[27] H. Wiendl,et al. HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation. , 2007, Blood.
[28] T. Glant,et al. Inhibition of indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates collagen-induced arthritis in mice , 2007, Arthritis research & therapy.
[29] D. Munn,et al. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. , 2007, The Journal of clinical investigation.
[30] A. Boasso,et al. Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells. , 2005, Blood.
[31] G. Prendergast,et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy , 2005, Nature Medicine.
[32] C. Fathman,et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation , 2003, Nature Medicine.
[33] F. Romerio,et al. Human primary CD4 + T cells activated in the presence of IFN-alpha 2b express functional indoleamine 2,3-dioxygenase. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[34] D. Munn,et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. , 1998, Science.
[35] Michael S. Krzemnicki,et al. Challenges and perspectives , 2009 .